

Application No.: 09/750,424

27656/37021

AMENDMENTS TO THE CLAIMS**In the Claims:**

Please amend claims 31 and 35-36 in the following manner. This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-30. (Canceled).

31. (Currently Amended) A method for the identification of intrabody frameworks or intrabodies of irrelevant antigen specificity which are soluble and stable in selected conditions comprising the following steps:

transformation of suitable host cells with a nucleic acid library, said library encoding a fusion product comprising an intrabody and a marker protein wherein said marker protein is only active as part of a fusion protein comprising an intrabody moiety which is soluble and stable and

culturing said cells under conditions allowing the identification and selection of cells expressing an intrabody moiety which is soluble and stable in the selected conditions by detection of the marker protein wherein the detection of the marker protein is not dependent upon the presence of an antigen for which the intrabody is specific.

32. (Canceled).

33. (Previously Presented) The method of claim 31, wherein said marker protein has a selectable activity.

34. (Previously Presented) The method of claim 33, wherein said marker protein has an enzymatic activity or fluorescence activity.

Application No.: 09/750,424

27656/37021

35. (Currently Amended) A method for the identification of intrabody frameworks or intrabodies of irrelevant antigen specificity which are soluble and stable in selected conditions comprising:

transformation of suitable host cells harboring a nucleic acid library said library encoding a fusion protein comprising an intrabody and a DNA binding protein that can activate transcription and said cells further comprise a marker gene encoding a detectable protein, said marker gene being under transcriptional control of said DNA binding protein, and

cultivation of said cells under conditions allowing the identification and selection of cells expressing a fusion protein comprising a soluble and stable intrabody in the selected conditions by detection of the protein encoded by said marker gene ~~wherein the detection of the marker protein is not dependent upon the presence of an antigen for which the intrabody is specific.~~

36. (Currently Amended) A method for the identification of intrabody frameworks or intrabodies of irrelevant antigen specificity which are soluble and stable in selected conditions comprising:

transformation of host cells with a DNA encoding a first protein comprising an intrabody and one part of a transactivation system and said cells further-express a second protein comprising at least the second part of said transactivation system, whereby said transactivation system is linked to a survival allowing marker gene which is under transcriptional control of said transactivation system and identifying cells expressing a first and a second protein interacting with each other via a constant region of the first protein by selecting for expression of said marker gene in the selected conditions.

Application No.: 09/750,424

27656/37021

37. (Previously Presented) The method of claim 36, wherein said first library encoded proteins comprises a transcriptional activation domain and said second proteins comprises a DNA binding domain or said first library encoded proteins comprises a DNA binding domain and said second proteins comprises a transcriptional activation domain.

38. (Previously Presented) The method of claim 36, wherein said second proteins comprises a DNA binding domain or a transactivation domain, respectively, and a protein interacting with a constant region of said first library encoded protein.

Claims 39-41 (Cancelled).

42. (Previously Presented) The method of claim 36 wherein said first library encoded protein comprises the transcription activation domain of GAL4 and Gal11P and said second protein comprises the DNA binding domain of Gal4.

43. (Previously Presented) The method of claim 31, wherein the host cell is an eukaryotic cell.

44. (Previously Presented) The method of claim 43, wherein the eukaryotic cell is a yeast cell.

45. (Previously Presented) The method of claim 31 wherein the selected conditions are reducing conditions.

Application No.: 09/750,424

27656/37021

46. (Previously Presented) The method of claim 35 wherein the selected conditions are reducing conditions.

47. (Previously Presented) The method of claim 36 wherein the selected conditions are reducing conditions.